Obstetrics & Gynaecology
Ovarian Hyperstimulation Syndrome (OHSS)
Classification and management of OHSS complicating assisted reproduction
Source: RCOG GTG 5 2016 / ESHRE
Step 1 of ~7
info
OHSS
OHSS: iatrogenic complication of ovarian stimulation (IVF/IUI). Incidence: 33% mild, 3–8% moderate, 0.1–2% severe. Cause: exaggerated ovarian response to hCG trigger. Risk factors: polycystic ovary morphology, young age, low BMI, previous OHSS, high AFC.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- Pramipexole (Restless Legs Syndrome — Elderly) · Dopamine Agonist (D2/D3 Receptor)
- Methotrexate (Ectopic) · Antimetabolite (Ectopic Pregnancy Management)
- Cabergoline (Hyperprolactinaemia / OHSS Prevention) · Dopamine Agonist — Hyperprolactinaemia / OHSS
Decision support only. Always apply local guidelines and clinical judgement.